Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills


Aetna says diet pills may be medically necessary and should be covered by insurance.

MINYANVILLE ORIGINAL Aetna (NYSE:AET), one of the country's largest health insurers, says a pair of recently approved diet pills are medically necessary, boosting the stocks of three weight-loss drug makers. The shares of Vivus (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA) and Orexigen Therapeutics (NASDAQ:OREX) jumped on the news.

In an updated clinical policy bulletin, Aetna says two drugs, Vivus' Qysmia and Arena's Belviq, should be covered if certain criteria is met.

The Aetna decision is significant because it means insured patients will receive at least some help paying for the drugs. The insurer's decision is also another step toward elevating the status of diet pills as medicines that treat a serious medical condition. In years past, these drugs were viewed as vanity products that carried severe side effect risks. In fact, the two diet drugs approved earlier this year marked the end of a 13-year period in which no weight loss pills were cleared for the US market. The events leading up to approval of the new drugs stirred a debate over the past few years that pitted medical need to treat a health epidemic vs. patient safety.

Aetna's decision is likely to be followed by other major insurers, who are also considering whether to cover new diet pills, Cowen & Co. analyst Simos Simeonidis predicts.

"We view the addition of Qsymia to this (insured) list as a positive development for Vivus and for the obesity pharmacotherapy space, in general, not only because Aetna is a major insurer in terms of number of lives covered, but also because it is significantly more difficult to get one of the large players in the space to make the first move towards reimbursement of a new class of drugs, than to have the other ones follow suit," Simeonidis says. He rates Vivus' stock a hold because he believes the sales ramp-up for Qysmia will continue to be slow.

Shares of Vivus rose 16% to $12 in late afternoon trading Wednesday. Arena moved up 3% to $9.19. Orexigen jumped 7% to $4.67. Orexigen is developing a drug, contrave, which is being tested for safety. Vivus' Qysmia was introduced to the market in September. Arena's Belviq is approved by the Food and Drug Administration but is awaiting a classification ruling from the Drug Enforcement Administration. (Belviq has a risk of abuse.)

There are restrictions to the Aetna coverage. The insurer requires their members to try to first lose weight through diet and exercise. The insured member also has to be measurably obese and, in many cases, show risk for other health problems. Some Aetna plans specifically exclude treatment for weight loss. Those plans would not cover the pills, Aetna says.

Still, the coverage decision is another vindication for Vivus, Arena and Orexigen, which have been arguing for the acknowledgement that obesity is a health epidemic in the US. A fat American population is contributing to many health problems, including heart disease, diabetes and even cancer.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos